As the third most commonly diagnosed cancer worldwide, and the second most lethal, colorectal cancer (CRC) is one of the most common diseases worldwide. Despite its value in guiding clinical management of colorectal cancer patients, solid biopsy carries several limitations, such as its invasiveness and inability to be used repeatedly. Clinical research directed toward the use of liquid biopsy, as an alternative to solid biopsy, has shown significant promise in several CRC clinical applications recently, including detecting CRC patients at an early stage, deciding how to treat them, monitoring their response, predicting relapses and metastases, unraveling tumor heterogeneity, and detecting minimal residual disease. The purpose of this short review is to describe the concept, the characteristics, the genetic components, and the technologies used in liquid biopsy in the context of colorectal cancer management, and we reviewed gene alterations, recently described in the literature, as promising potential biomarkers that may be used specifically in liquid biopsy tests. Liquid biopsy provides a noninvasive method of collecting samples for analysis of circulating tumor cells (CTCs) and genomic material, such as cell-free DNA (cfDNA), as a complementary biopsy to solid tumor tissue. Solid biopsies are critical for molecular characterization and diagnosis at the time of collection. The liquid biopsy offers longitudinal molecular characterization of the disease, which is crucial for precision medicine and patient-centered care. We provide an overview of CRC and the different methodologies for detecting CTCs and cfDNA, followed by a discussion of the potential clinical utility of liquid biopsy in CRC patient care, and finally, current challenges. Increasing colorectal cancer cases and increasing demand for minimally invasive procedures and advanced cancer treatments are driving the growth of the colorectal cancer liquid biopsy market. Additionally, the increase in healthcare expenditures, the availability of skilled professionals, the increase in R D activities to develop and launch novel therapies, and technological advancements in the field of oncology boost the colorectal cancer liquid biopsy market. Recent advances have not yet achieved the desired specificity and sensitivity. The growth of the market may be hindered by this factor. The growing interest in liquid biopsy, however, may offer new opportunities for the industry
FutureWise Market Research has instantiated a report that provides an intricate analysis of Colorectal Cancer Liquid Biopsy Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Colorectal Cancer Liquid Biopsy Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.